Cytori and GE Healthcare Form Partnership to Commercialize StemSource in the U.S
News May 11, 2009
Cytori Therapeutics and GE Healthcare announce an agreement by which GE Healthcare will commercialize Cytori’s StemSource® technology in the North American stem cell banking and research markets.
The StemSource technology includes automated equipment to process stem and regenerative cells found in adipose tissue, cryopreserve them or use them directly for research purposes.
In January 2009, Cytori and GE Healthcare formed a separate agreement to commercialize Cytori’s products in ten European countries. This includes selling the Celution® 800/CRS System in the European cosmetic and reconstructive surgery market as well as selling StemSource products in the European cell banking and research markets.
The partnership entered is similar in nature to the European agreement, but is limited to the sale of StemSource banking and research products in the U.S., Canada and Mexico for 18 months starting in the second quarter of 2009. The agreement does not include U.S. commercialization of Cytori’s Celution System, which is currently under review by the FDA.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019